<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894721</url>
  </required_header>
  <id_info>
    <org_study_id>5077/410 CH 2020</org_study_id>
    <nct_id>NCT04894721</nct_id>
  </id_info>
  <brief_title>Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)</brief_title>
  <acronym>IVERNEX-TUC</acronym>
  <official_title>Study of Efficacy and Safety of Ivermectin for COVID-19 Prophylaxis in Post-exposure Contact or Epidemiological Link</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Public Health, Argentina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Public Health, Argentina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled clinical trial on using oral ivermectin in COVID-19 prophylaxis&#xD;
      supplying the drug to close contacts of confirmed cases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, and controlled clinical trial that aims to evaluate the&#xD;
      use of oral ivermectin in COVID-19 prophylaxis. The study has two arms in a relationship of&#xD;
      2:1: Experimental Group (EG n=500) and Placebo Group (CG n=250).&#xD;
&#xD;
      The sample size was calculated by applying a two-proportion comparison test. Type of&#xD;
      two-sided test, 95% confidence or safety level (1-α), 95% statistical power, 75% P1&#xD;
      (proportion in the placebo group), 65% P2 (proportion in the new treatment or intervention&#xD;
      group), size sample without adjustment (n = 543), 25% expected proportion of losses, n= 724&#xD;
      sample adjusted for losses.&#xD;
&#xD;
      The hypothesis of the study is that treatment with ivermectin may decrease the chance of&#xD;
      occurrence/progress of clinical manifestations and onset of severe disease. Whereas control&#xD;
      of the contagion on the first days of development of the disease, this treatment with&#xD;
      ivermectin in suspected cases of COVID-19 (by epidemiological nexus) would contribute to the&#xD;
      control of contagion at the first part of the infection, even in the absence of symptoms.&#xD;
&#xD;
      Categorical variables will be represented with frequencies and proportions, while continuous&#xD;
      quantitative variables will be expressed as mean ± standard deviation (SD) or as median and&#xD;
      interquartile range (IQR). The proportions will be compared using Pearson's Chi-square test&#xD;
      or Fisher's exact test as appropriate, and continuous quantitative variables with Student's t&#xD;
      test. The estimation of the efficacy of intensive treatment with Ivermectin will be&#xD;
      calculated using Kaplan-Meier curves and the differences will be analyzed by means of the&#xD;
      log-rank test. The risk will be calculated as a ratio of advantages for Intensive treatment&#xD;
      with Ivermectin (Odds Ratio, OR) with its 95% confidence intervals (95% CI). A value of p&#xD;
      &lt;0.05 will be considered significant. Analyzes will be performed using Stata 11.2 software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled. Experimental and Control Group in relationship of 2:1</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects who were diagnosed with COVID-19 in EG and CG (Negative polymerase chain reaction - real-time).</measure>
    <time_frame>At 2 weeks</time_frame>
    <description>Pearson's Chi-square and proportion test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contagion risk.</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Odd Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prophylactic effect associated with patient's preexisting comorbidity</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Logistic regression test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The EG receives ivermectin 0,6mg/kg of weight orally on days 1 (one) and 7 (seven) plus standard biosecurity care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The CG receives a placebo on days 1 (one) and 7 (seven) plus standard biosecurity care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>0,6mg/kg of weight orally on days 1 and 7</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>Iver</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A substance with similar physical characteristics as ivermectin, without the active drug ingredient</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years either sex&#xD;
&#xD;
          -  Women of childbearing age with a negative pregnancy test&#xD;
&#xD;
          -  In close contact group or epidemiological nexus of a positive COVID-19 case&#xD;
&#xD;
          -  Able to understand and grant informed consent&#xD;
&#xD;
          -  Real-time - polymerase chain reaction test with a negative result&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to any component of the drug under evaluation&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Use of immunosuppressants (including systemic corticosteroids) in the last 30 days&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Patients with other acute infectious diseases&#xD;
&#xD;
          -  Patients with autoimmune disease and/or chronic decompensated diseases&#xD;
&#xD;
          -  Who have received a vaccine for COVID-19 (1/2 dose) or that have taken ivermectin&#xD;
             (prior to 30 days of the study) or who are participating in another COVID-19&#xD;
             prophylaxis study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rossana Chahla, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Public Health, Tucumán, Argentina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Peral, Ph.D.</last_name>
    <phone>+54 381 3311919</phone>
    <email>mperal@fm.unt.edu.ar</email>
  </overall_contact>
  <location>
    <facility>
      <name>SI.PRO.SA, Ministerio de Salud Pública</name>
      <address>
        <city>Tucumán</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Peral, Ph.D.</last_name>
      <phone>03814468999</phone>
      <email>mperal0150@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature. 2007 Aug 9;448(7154):645-6.</citation>
    <PMID>17687303</PMID>
  </reference>
  <reference>
    <citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.</citation>
    <PMID>32251768</PMID>
  </reference>
  <reference>
    <citation>Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021 Feb;103:214-216. doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2.</citation>
    <PMID>33278625</PMID>
  </reference>
  <reference>
    <citation>Ahmed Elgazzar, Basma Hany, Shaimaa Abo Youssef et al. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic, 13 November 2020, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-100956/v1]</citation>
  </reference>
  <reference>
    <citation>Hirsch RR, Carvallo, Héctor E. Ivermectin as Prophylaxis Against COVID-19 Retrospective Cases Evaluation. Microbiol Infect Dis. 2020; 4(4): 1-8.</citation>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Public Health, Argentina</investigator_affiliation>
    <investigator_full_name>Maria de los Angeles Peral de Bruno</investigator_full_name>
    <investigator_title>Ph.D in Biological Science</investigator_title>
  </responsible_party>
  <keyword>Ivermectin</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Epidemiological link</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04894721/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04894721/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

